Literature DB >> 29859231

A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis.

Adam M Swartz1, Elizabeth Reap2, Pamela Norberg2, Robert Schmittling2, Sylvia Janetzki3, Luis Sanchez-Perez2, John H Sampson4.   

Abstract

The ELISpot assay prevails as one of the most sensitive and meaningful assays for the detection of antigen-specific, effector immune responses. Acquisition of cellular analyte for ELISpot analysis is typically not problematic when derived from tissues enriched in lymphocytes (e.g., lymphoid organs and blood); however, cell processing becomes more difficult when lymphocytes represent only a very minor population relative to the source tissue, especially when the source tissue is in limited supply (e.g., small mouse tumors). Traditional enzymatic-based methods for dissociating tumors often result in poor yields, inconsistent lymphocyte enrichment, and can have deleterious effects on lymphocyte phenotype and function. To address these limitations, we have developed an enzyme-free protocol for processing tumor infiltrating lymphocytes (TILs) from small mouse tumors, which enables the enumeration of antigen-specific effector lymphocytes using ELISpot analysis. This procedure is predicated on the dissociation of tumor tissue using gentle agitation with a paddle blender followed by a brief in vitro culture period to remove adherent cells, as well as to revive lymphocytes from a non-responsive state. Although this method is demonstrated with mouse intracerebral tumors, we have found that this protocol is applicable to peripheral tumors and may likely extend to alternative tissue sources wherein lymphocytes exist in low numbers.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ELISpot; TIL; Tumor infiltrating lymphocyte

Mesh:

Substances:

Year:  2018        PMID: 29859231      PMCID: PMC6037182          DOI: 10.1016/j.jim.2018.05.015

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  A T cell clone's avidity is a function of its activation state.

Authors:  M D Hesse; A Y Karulin; B O Boehm; P V Lehmann; M Tary-Lehmann
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

2.  Guidelines for the automated evaluation of Elispot assays.

Authors:  Sylvia Janetzki; Leah Price; Helene Schroeder; Cedrik M Britten; Marij J P Welters; Axel Hoos
Journal:  Nat Protoc       Date:  2015-06-25       Impact factor: 13.491

3.  Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells.

Authors:  C Czerkinsky; G Andersson; H P Ekre; L A Nilsson; L Klareskog; O Ouchterlony
Journal:  J Immunol Methods       Date:  1988-05-25       Impact factor: 2.303

4.  Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells.

Authors:  Giuliana P Mognol; Roberto Spreafico; Victor Wong; James P Scott-Browne; Susan Togher; Alexander Hoffmann; Patrick G Hogan; Anjana Rao; Sara Trifari
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-10       Impact factor: 11.205

5.  Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.

Authors:  A Prévost-Blondel; C Zimmermann; C Stemmer; P Kulmburg; F M Rosenthal; H Pircher
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

6.  HLA class I binding 9mer peptides from influenza A virus induce CD4 T cell responses.

Authors:  Mingjun Wang; Mette V Larsen; Morten Nielsen; Mikkel Harndahl; Sune Justesen; Morten H Dziegiel; Søren Buus; Sheila T Tang; Ole Lund; Mogens H Claesson
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

7.  Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment.

Authors:  W M Mulder; H Koenen; A J van de Muysenberg; E Bloemena; J Wagstaff; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 8.  Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Authors:  Linda Wooldridge; Anna Lissina; David K Cole; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

Review 9.  Detecting Antigen-Specific T Cell Responses: From Bulk Populations to Single Cells.

Authors:  Chansavath Phetsouphanh; John James Zaunders; Anthony Dominic Kelleher
Journal:  Int J Mol Sci       Date:  2015-08-12       Impact factor: 5.923

Review 10.  Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays.

Authors:  Sandra A Calarota; Fausto Baldanti
Journal:  Clin Dev Immunol       Date:  2013-11-11
  10 in total
  1 in total

1.  A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.

Authors:  Adam M Swartz; Kendra L Congdon; Smita K Nair; Qi-Jing Li; James E Herndon; Carter M Suryadevara; Katherine A Riccione; Gary E Archer; Pamela K Norberg; Luis A Sanchez-Perez; John H Sampson
Journal:  NPJ Vaccines       Date:  2021-01-18       Impact factor: 7.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.